Napo Pharmaceuticals, a Jaguar Health Family Company, will exhibit at the Oncology Nursing Society (ONS) Congress from April 24-28, 2024 in Washington, DC. The company aims to drive awareness among the oncology nursing community about Jaguar's expanding focus on cancer supportive care. Jaguar is expanding its footprint beyond HIV-related supportive care to include cancer-related supportive care. The company recently in-licensed the oral mucositis product Gelclair, which is a protective gel indicated for the management of pain and relief of pain caused by oral lesions. Jaguar is also awaiting results for its pivotal Phase 3 trial of crofelemer for cancer therapy-related diarrhea. The company will feature its patient advocacy program called 'Make Cancer Less Shitty' at the ONS Congress. The program aims to drive awareness of cancer supportive care gaps and needs and bring together patients, advocates, researchers, and clinicians. Napo Pharmaceuticals is a Jaguar family company focused on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. [52afa169]